This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Longobardi, S. Articles by Saccà, L. Search for Related Content PubMed PubMed Citation Articles by Longobardi, S. Articles by Saccà, L.

Growth Hormone (GH) Effects on Bone and Collagen Turnover in Healthy Adults and Its Potential as a Marker of GH Abuse in Sports: A Double Blind, Placebo-Controlled Study¹

Department of Clinical Medicine and Cardiovascular Sciences, University Federico II (S.L., A.C., L.S.), 80131 Naples, Italy; Department of Endocrinology, St. Thomas’s Hospital (N.K., M.A.B., C.P., J.P.), London SE1 7EH, United Kingdom; Research Center for Endocrinology and Metabolism, Sahlgrenska Hospital (C.E., T.R.), S-41345 Göteborg, Sweden; Department of Endocrinology, Aarhus Community Hospital (R.D., J.O.J.), Aarhus, Denmark; and Institute of Mathematics and Statistics, University of Kent (E.E.B.), Canterbury, Kent CT2 7NF, United Kingdom

Address all correspondence and requests for reprints to: Luigi Saccà, M.D., Department of Internal Medicine, via Pansini 5, 80131 Naples, Italy. E-mail: sacca{at}unina.it

The effects of GH on bone remodeling in healthy adults have not been systematically investigated. An analysis of these effects might provide insights into GH physiology and might yield data useful for the detection of GH doping in sports. The aim of this study was to evaluate the effects of GH administration on biochemical markers of bone and collagen turnover in healthy volunteers. Ninety-nine healthy volunteers of both sexes were enrolled in a multicenter, randomized, double blind, placebo-controlled study and assigned to receive either placebo (40 subjects) or recombinant human GH (0.1 IU/kg·day in 29 subjects and 0.2 IU/kg·day in 30 subjects). The treatment duration was 28 days, followed by a 56-day wash-out period. The biochemical markers evaluated were the bone formation markers osteocalcin and C-terminal propeptide of type I procollagen, the resorption marker type I collagen telopeptide, and the soft tissue marker procollagen type III. All variables increased on days 21 and 28 in the two active treatment groups vs. levels in both the baseline (P < 0.01) and placebo (P < 0.01) groups. The increment was more pronounced in the 0.2 IU/kg·day group and remained significant on day 84 for procollagen type III (from 0.53 ± 0.13 to 0.61 ± 0.14 kU/L; P < 0.02) and osteocalcin (from 12.2 ± 2.9 to 14.6 ± 3.6 UG/L; P < 0.02), whereas levels of C-terminal propeptide of type I procollagen and type I collagen telopeptide declined after day 42 and were no longer significantly above baseline on day 84 (from 3.9 ± 1.2 to 5.1 ± 1.5 µg/L and from 174 ± 60 to 173 ± 53 µg/L, respectively). Gender-related differences were observed in the study; females were less responsive than males to GH administration with respect to procollagen type III and type I collagen telopeptide (P < 0.001).

In conclusion, exogenous GH administration affects the biochemical parameters of bone and collagen turnover in a dose- and gender-dependent manner. As GH-induced modifications of most markers, in particular procollagen type III and osteocalcin, persist after GH withdrawal, they may be suitable markers for detecting GH abuse.

This article has been cited by other articles:

				A. E. Nelson, U. Meinhardt, J. L. Hansen, I. H. Walker, G. Stone, C. J. Howe, K.-c. Leung, M. J. Seibel, R. C. Baxter, D. J. Handelsman, et al. Pharmacodynamics of Growth Hormone Abuse Biomarkers and the Influence of Gender and Testosterone: A Randomized Double-Blind Placebo-Controlled Study in Young Recreational Athletes J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2213 - 2222. [Abstract] [Full Text] [PDF]

				H. Liu, D. M. Bravata, I. Olkin, A. Friedlander, V. Liu, B. Roberts, E. Bendavid, O. Saynina, S. R. Salpeter, A. M. Garber, et al. Systematic Review: The Effects of Growth Hormone on Athletic Performance Ann Intern Med, May 20, 2008; 148(10): 747 - 758. [Abstract] [Full Text] [PDF]

				J. Gibney, M.-L. Healy, and P. H. Sonksen The Growth Hormone/Insulin-Like Growth Factor-I Axis in Exercise and Sport Endocr. Rev., October 1, 2007; 28(6): 603 - 624. [Abstract] [Full Text] [PDF]

				A. Keller, Z. Wu, J. Kratzsch, E. Keller, W. F Blum, A. Kniess, R. Preiss, J. Teichert, C. J Strasburger, and M. Bidlingmaier Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration Eur. J. Endocrinol., June 1, 2007; 156(6): 647 - 653. [Abstract] [Full Text] [PDF]

				A. E. Nelson, C. J. Howe, T. V. Nguyen, K.-C. Leung, G. J. Trout, M. J. Seibel, R. C. Baxter, D. J. Handelsman, R. Kazlauskas, and K. K. Ho Influence of Demographic Factors and Sport Type on Growth Hormone-Responsive Markers in Elite Athletes J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4424 - 4432. [Abstract] [Full Text] [PDF]

				M Saugy, N Robinson, C Saudan, N Baume, L Avois, and P Mangin Human growth hormone doping in sport Br. J. Sports Med., July 1, 2006; 40(suppl_1): i35 - i39. [Abstract] [Full Text] [PDF]

				L. Chung, D. Clifford, M. Buckley, and R. C. Baxter Novel Biomarkers of Human Growth Hormone Action from Serum Proteomic Profiling Using Protein Chip Mass Spectrometry J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 671 - 677. [Abstract] [Full Text] [PDF]

				C. M. McHugh, R. T. Park, P. H. Sonksen, and R. I.G. Holt Challenges in Detecting the Abuse of Growth Hormone in Sport Clin. Chem., September 1, 2005; 51(9): 1587 - 1593. [Abstract] [Full Text] [PDF]

				M.-L. Healy, R. Dall, J. Gibney, E. Bassett, C. Ehrnborg, C. Pentecost, T. Rosen, A. Cittadini, R. C. Baxter, and P. H. Sonksen Toward the Development of a Test for Growth Hormone (GH) Abuse: A Study of Extreme Physiological Ranges of GH-Dependent Markers in 813 Elite Athletes in the Postcompetition Setting J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 641 - 649. [Abstract] [Full Text] [PDF]

				M J Rennie Claims for the anabolic effects of growth hormone: a case of the Emperor's new clothes? Br. J. Sports Med., April 1, 2003; 37(2): 100 - 105. [Abstract] [Full Text] [PDF]

				C. Ehrnborg, K. H. W. Lange, R. Dall, J. S. Christiansen, P.-A. Lundberg, R. C. Baxter, M. A. Boroujerdi, B.-A. Bengtsson, M.-L. Healey, C. Pentecost, et al. The Growth Hormone/Insulin-Like Growth Factor-I Axis Hormones and Bone Markers in Elite Athletes in Response to a Maximum Exercise Test J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 394 - 401. [Abstract] [Full Text] [PDF]

				J. D. Wallace, R. C. Cuneo, M. Bidlingmaier, P. A. Lundberg, L. Carlsson, C. L. Boguszewski, J. Hay, M. Boroujerdi, A. Cittadini, R. Dall, et al. Changes in Non-22-Kilodalton (kDa) Isoforms of Growth Hormone (GH) after Administration of 22-kDa Recombinant Human GH in Trained Adult Males J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1731 - 1737. [Abstract] [Full Text]